All In Biotech

Drug Trial Radar · NCT07808905

Evaluate the Efficacy and Safety of EN001 in Patients With Sarcopenia

A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 1/2 Clinical Trial to Evaluate the Efficacy and Safety of EN001 in Patients With Sarcopenia

Last checked: Nov 20, 2026Latest source record: Sep 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 132 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

132

Planned (sponsor's estimate)

Start

Mar 1, 2027

Primary completion

Oct 31, 2029

Study completion Oct 31, 2029

Sponsor

Lead sponsor
ENCellIndustry
Sponsor type
Industry
First posted
Sep 9, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 1/2 Clinical Trial to Evaluate the Efficacy and Safety of EN001 in Patients with Sarcopenia

Conditions

  • Sarcopenia

Interventions

  • EN001Drug

    \- Phase1-Cohort 1: EN001 Low dose administered intravenously (IV) 3 times at 4 week intervals.

  • EN001Drug

    -Phase2-Cohort 2 : EN001 Medium dose administered intravenously (IV) 3times at 4 week intervals.

  • EN001Drug

    -Phase1-Cohort 3 : EN001 High dose administered intravenously (IV) 3times at 4 week intervals.

  • EN001Drug

    -Phase2-Cohort 1 : EN001 Low dose(Recommended Phase 2 Dose\[RP2D\] of EN001) administered intravenously (IV) 3times at 4 week intervals.

  • EN001Drug

    -Phase2-Cohort2 : EN001 High dose(Recommended Phase 2 Dose\[RP2D\] of EN001) administered intravenously (IV) 3times at 4 week intervals.

  • EN001 PlaceboDrug

    -Phase2-Placebo : EN001 Placebo administered intravenously (IV) 3times at 4 week intervals.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. [Phase1] Dose limiting toxicity (DLT) and adverse drug reactions related to discontinuation of investigational product administrationTime frame: Up to 12 weeks
  2. [Phase2] Change from baseline in the SPPB(Short Physical Performance Battery) at Week 24Time frame: at Week 24

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Samsung Medical Center

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.